Literature DB >> 15000431

Characterization of ibuproxam binary and ternary dispersions with hydrophilic carriers.

M Cirri1, P Mura, A M Rabasco, J M Ginés, J R Moyano, M L Gònzalez-Rodrìguez.   

Abstract

This work investigates the possibility of increasing the dissolution properties of ibuproxam (a poorly water-soluble anti-inflammatory drug) using hydrophilic carriers such as polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), or urea, alone or in combination. Phase-solubility studies showed that the carrier solubilizing power was in the order PEG>PVP>urea and evidenced a synergistic effect in drug solubility improvement when using carrier combinations. Binary and ternary systems, at 20/80 or 20/40/40 (w/w) drug/carrier(s) ratios, prepared by coevaporation of their ethanolic solutions or by cogrinding physical mixtures in a high-energy vibrational micromill, were characterized by differential scanning calorimetry (DSC), hot stage microscopy (HSM), and scanning electron microscopy (SEM) analyses. The results of dissolution tests (USP paddle method), in terms of Dissolution Efficiency, indicated that ternary systems were up to 35% more effective than the corresponding binary preparations and coevaporated products were up to 45% more efficacious than the corresponding coground ones. The IBUX-PEG-PVP coevaporated was the best product, allowing a more than three-times increase in Dissolution Efficiency with respect to drug alone; moreover, t50% (> 60 min for pure ibuproxam) was < 10 min, and 90% dissolution was achieved after 30 min, whereas only 40% was obtained after 60 min for pure drug. The best performance of this system was attributed to a joined effect of the strong amorphizing power of PVP (as demonstrated by solid state analyses) with the high solubilizing efficacy of PEG (as emerged from phase-solubility studies). The drug dissolution rate from solid dispersions remained practically unchanged after one-year storage at room temperature in closed containers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15000431     DOI: 10.1081/ddc-120027513

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  7 in total

1.  Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.

Authors:  Sanjay Verma; Varma S Rudraraju
Journal:  AAPS PharmSciTech       Date:  2015-02-12       Impact factor: 3.246

2.  Kneading technique for preparation of binary solid dispersion of meloxicam with poloxamer 188.

Authors:  Mowafaq M Ghareeb; Alaa A Abdulrasool; Ahmed A Hussein; Mohammed I Noordin
Journal:  AAPS PharmSciTech       Date:  2009-10-28       Impact factor: 3.246

3.  Improvement in Dissolution Rate of Cefuroxime Axetil by using Poloxamer 188 and Neusilin US2.

Authors:  J Sruti; Ch N Patra; S K Swain; S Beg; H R Palatasingh; S C Dinda; M E Bhanoji Rao
Journal:  Indian J Pharm Sci       Date:  2013-01       Impact factor: 0.975

4.  Mangosteen pericarp extract embedded in electrospun PVP nanofiber mats: physicochemical properties and release mechanism of α-mangostin.

Authors:  Ida Sriyanti; Dhewa Edikresnha; Annisa Rahma; Muhammad Miftahul Munir; Heni Rachmawati; Khairurrijal Khairurrijal
Journal:  Int J Nanomedicine       Date:  2018-08-31

5.  Improvement of solubility and dissolution properties of clotrimazole by solid dispersions and inclusion complexes.

Authors:  Gehan Balata; M Mahdi; Rania Abu Bakera
Journal:  Indian J Pharm Sci       Date:  2011-09       Impact factor: 0.975

6.  Characterization of olanzapine-solid dispersions.

Authors:  Venkateskumar Krishnamoorthy; Arunkumar Nagalingam; Verma Priya Ranjan Prasad; Siva Parameshwaran; Neema George; Punitha Kaliyan
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

7.  Rapid disintegrating tablets of simvastatin dispersions in polyoxyethylene-polypropylene block copolymer for maximized disintegration and dissolution.

Authors:  Gehan F Balata; Ahmad S Zidan; Mohamad As Abourehab; Ebtessam A Essa
Journal:  Drug Des Devel Ther       Date:  2016-10-03       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.